Cloudtag Inc (LON:CTAG) CEO Amit Ben-Haim talks to DirectorsTalk about the receipt of the first lot of production units and what this means for the company, what they are hoping to see from these further tests and the next steps for CloudTag inc.
Amit Ben-Haim has a proven track record as a successful entrepreneur establishing, leading and expanding companies through to trade sale exits as co-founder, executive and non-executive director. In 1993, he co-founded Biosense Inc., a medical devices company which was sold to Dow Jones-listed Johnson & Johnson in 1997 for $485 million. In 1996, he co-established Impulse Dynamics Inc., another medical devices company, which ultimately licensed its cardiac contractility technology to NYSE-listed Guidant Corporation (a group company of Boston Scientific) and in 1998 he was one of several founders of Odigo Inc., a communications company specialising in instant messaging platforms (for example Blackberry’s BBM) which was sold in 2002 to NASDAQ-listed Comverse Inc. Amit’s experience extends across various industries including aviation (private and commercial), infrastructure, corporate finance and wealth management. He has expertise in risk and regulatory compliance for listed companies and is a director of SB Corporate Finance Partners Limited which is authorised by the Financial Conduct Authority to advise on and/or arrange certain investments in the UK.
CloudTag Inc brings accurate data and performance monitoring to the health, wellbeing and fitness markets; in a way that is easy to understand and allows the user to make positive changes to their health and fitness lifestyle regime, the company is listed on the Alternative Investment Market (AIM) in London, United Kingdom.
